To the Editor: One group of immune complex vasculitides (IC-V) was considered to be caused by (peri)vascular deposits of large precipitating IC of immunoglobulin (Ig) M or IgG, based on the concept of serum-sickness or the Arthus-reaction, with drugs or microbes presenting the eliciting antigens.1,2 This IC-V was termed hypersensitivity or cutaneous leukocytoclastic vasculitis; and, lately, IgG/IgM-vasculitis (IgG/IgMV),3,4 to distinguish it from (1) IgA-vasculitis, given their overlapping clinical, but presumably different pathophysiologic features (hypogalactosylated IgA1 in IgAV) and (2) other IC-V associated with IgM/IgG-deposits which, however, involve special, defined IC (cryoglobulins in cryoglobulinemic-vasculitis; IgM-rheumatoid factor in rheumatoid-vasculitis, anti-C1q in hypocomplementemic urticarial vasculitis) or additional disease-related mechanisms as in systemic lupus erythematosus (SLE)-associated-vasculitis or Sjögren's syndrome-vasculitis. (Peri)vascular Ig deposits may also occur in cases of ANCA-associated vasculitides (AAV).
When hypogalactosidated IgA1 was discovered to present a major pathophysiological component in IgAV, the concept of IgG/IgMV had not been extensively pursued. Therefore, this multicenter retrospective study by the EADV-Vasculitis-Taskforce investigated the existence and frequency of idiopathic IgM/IgGV.
Data were collected from 2017 until May 2024 in the Dermatology Departments of Florence, Milan, and Antalya, where vasculitis cases were documented according to a standard operating procedure previously consented by the EADV-Taskforce. Inclusion criteria were: (1) palpable purpura; (2) histologically confirmed leukocytoclastic vasculitis with (peri)vascular IgM and/or IgG, but without IgA (immunofluorescence analyzed by the skin-immunopathology-laboratory, Florence); and (3) follow-up ≥18 months.
Among all archived small-vessel-vasculitides 90 cases were retrieved with (peri)vascular deposition of IgG or IgM, but no IgA (Table I). Of these, 45 had to be excluded because data necessary to indicate or exclude other forms of vasculitis were missing (Table II), and 2, because a second biopsy had revealed presence of (peri)vascular IgA. Of the remaining 43 cases, 7 revealed another defined vasculitis: 3 AAV, 3 vasculitis in Sjögren's syndrome and 1 in SLE. Consequently, 36 of the 43 patients fulfilled the complete criteria for idiopathic IgG/IgMV. None of these cases exhibited systemic involvement and of 33 patients followed up until August 2025, only 1 had relapsed.
Table I.
Results of direct immunofluorescence
| DIF results | Florence | Milan | Antalya | |
|---|---|---|---|---|
| Total | 20 | 11 | 5 | |
| (peri)vascular IgG | 0 | 0 | 3 | 3 (8.33% of all idiopathic IgG/IgMV) |
| (peri)vascular IgM | 16 | 11 | 2 | 29 (80.6%) |
| both (peri)vascular IgG and IgM | 4 | 0 | 0 | 4 (11.1%) |
IgG, Immunoglobulin G; IgM, immunoglobulin M.
Table II.
Idiopathic IgM/IgGV cases during the study period related to all histologically confirmed small vessel vasculitides, and number of vasculitides with exclusively (peri)vascular IgG/IgM-deposits prior to exclusion of those with incomplete data and after exclusion of those whose data indicated presence of another form of IC-vasculitis or of AAV. Data shown for each of the 3 centers
| Florence | Milan | Antalya | Total | |
|---|---|---|---|---|
| Number of histologically confirmed small vessel vasculitides | 155 | 126 | 55 | 336 |
| Confirmed IC-V with exclusively IgG/IgM deposits in initial biopsy (with complete or incomplete sets of laboratory data) | 50 (32.3%) | 27 (21.4%) | 13 (23.6%) | 90 (26.7% of all histologically confirmed small vessel vasculitides) |
| Confirmed IC-V with exclusively IgG/IgM deposits in initial biopsy and with complete datasets | 24 (15.4%) | 14 (11.1%) | 7 (12.7%) | 45 (13.4%) |
| Idiopathic IgM/IgGV (after exclusion of cases with other defined IC-V such cryoglobulinemic, Sjögren's and SLE vasculitis or of cases with AAV and of cases with IgA in subsequent biopsies) | 20 (12.9%) | 11 (8.7%) | 5 (9.0%) | 36 (10.7%) |
AAV, ANCA-Associated vasculitides; IC-V, immune complex vasculitides; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M.
These findings would comply with the existence of idiopathic IgG/IgMV as a distinct entity. They also indicate that it is likely infrequent and benign. Confirmation of its diagnosis, however, requires the described comprehensive evaluation to exclude and to not overlook another form of vasculitis, such as AAV, Sjögren's syndrome-vasculitis or SLE-vasculitis—as observed in this cohort—or cryoglobulinemic or rheumatoid-vasculitis as shown in other reports.2, 3, 4, 5 Previous immunofluorescence studies on IC-V have revealed considerable variability in frequency of exclusively (peri)vascular IgM/IgG, and often lacked the complete clinical and pathological data necessary to sufficiently differentiate between different IC-V (reviewed in5)—a deficiency that even in our cohort forced exclusion of several initially identified cases.
Other reasons for (exclusively) IgG/IgM deposits could be (1) opsonization of necrotic endothelium for clearance by phagocytes, which, however, would presumably occur later and not only around clearly discernible vascular structures, or (2) failure to detect IgA, which may occur (as in the 2 cases we excluded, because a second biopsy had revealed IgA), but which is unlikely to have occurred in all our biopsies.
In conclusion, it is clinically relevant to differentiate between IgG/IgMV and other IC-V.
Conflicts of interest
None disclosed.
Footnotes
Funding sources: Research and teaching budget of Professor Cord Sunderkötter and Professor Marzia Caproni.
IRB approval status: The Tuscany Region Ethics Committee – Pediatric (CERT-P) approved the protocol Vasculitis IgM/IgG ver. 1.0 19 February 2024.
Patient consent: Patient consent was obtained from the patients involved in the study to collect their data. The protocol was approved by the institutional review board.
References
- 1.Schifferli J.A., Taylor R.P. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989;35:993–1003. doi: 10.1038/ki.1989.83. [DOI] [PubMed] [Google Scholar]
- 2.Sunderkötter C., Golle L., Pillebout E., Michl C. Pathophysiology and clinical manifestations of immune complex vasculitides. Front Med (Lausanne) 2023;10 doi: 10.3389/fmed.2023.1103065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sunderkötter C.H., Zelger B., Chen K.R., et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol. 2018;70:171–184. doi: 10.1002/art.40375. [DOI] [PubMed] [Google Scholar]
- 4.Michel B.A., Hunder G.G., Bloch D.A., Calabrese L.H. Hypersensitivity vasculitis and Henoch-Schonlein purpura: a comparison between the 2 disorders. J Rheumatol. 1992;19:721–728. [PubMed] [Google Scholar]
- 5.Herda L., Michl C., Sunderkötter C. High detection rate for perivascular deposits of immunoglobulins in immune complex vasculitis from biopsies of early macular lesions. J Dtsch Dermatol Ges. 2025;23:479–485. doi: 10.1111/ddg.15636. [DOI] [PMC free article] [PubMed] [Google Scholar]